Urban Wealth Management LLC Lowers Position in CVS Health Corporation $CVS

Urban Wealth Management LLC trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 18.6% during the 1st quarter, Holdings Channel reports. The fund owned 28,862 shares of the pharmacy operator’s stock after selling 6,589 shares during the period. CVS Health comprises about 2.1% of Urban Wealth Management LLC’s portfolio, making the stock its 11th largest position. Urban Wealth Management LLC’s holdings in CVS Health were worth $2,073,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Kingsview Wealth Management LLC boosted its position in CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after purchasing an additional 79,340 shares in the last quarter. Intech Investment Management LLC raised its holdings in CVS Health by 50.3% in the third quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock worth $6,526,000 after purchasing an additional 28,953 shares in the last quarter. Hamlin Capital Management LLC bought a new position in CVS Health in the fourth quarter worth about $160,844,000. Cresset Asset Management LLC lifted its position in shares of CVS Health by 56.8% during the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock valued at $2,675,000 after buying an additional 12,849 shares during the last quarter. Finally, Capitolis Liquid Global Markets LLC bought a new stake in shares of CVS Health in the 3rd quarter valued at about $11,308,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding its direct-to-consumer GLP-1 weight-loss program, which could support new growth and improve margins if demand continues. CVS expands direct-to-consumer GLP-1 weight-loss program
• Positive Sentiment: Analysts/valuation updates have nudged CVS’s implied fair value higher, reflecting improving views on GLP-1 engagement, margins, and earnings resilience. CVS Health (CVS) Stock Sees Modest Fair Value Lift As GLP 1 And Margins Help
• Positive Sentiment: CVS Health Foundation announced $2 million in combined grants to Hartford- and Rhode Island-area nonprofits, reinforcing community ties and its local health access message. CVS Health Foundation invests $1 million in Hartford nonprofits tackling community health needs
• Positive Sentiment: CVS won a whistleblower drug lawsuit, removing a potential legal overhang. CVS Health Beats Whistleblower’s Worthless Services Drug Suit

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CVS shares. Truist Financial boosted their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Sanford C. Bernstein increased their price objective on CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. boosted their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Argus increased their price target on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. Finally, Leerink Partners restated an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $101.28.

CVS Health Stock Performance

Shares of CVS stock opened at $104.50 on Friday. The business has a fifty day moving average of $91.23 and a 200 day moving average of $82.24. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $104.94. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $133.33 billion, a price-to-earnings ratio of 46.03, a price-to-earnings-growth ratio of 1.00 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.